Imatinib for hepatocellular cancer - Focus on pharmacokinetic/pharmacodynamic modelling and liver function

Cancer Letters

Volumn 260, Issue 1-2, 2008, Pages 146-154

  Treiber, G ^a,d   Wex, T ^a   Schleyer, E ^b   Troeger, U ^a   Hosius, C ^c   Malfertheiner, P ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b Carl von Basedow Hospital   (Germany)

^c Novartis Oncology ^*  (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

Hepatocellular cancer; Imatinib; Liver function; Phamacodynamics; Pharmakokinetics; Platelet derived growth factor

Indexed keywords

ALPHA FETOPROTEIN; DRUG METABOLITE; IMATINIB; NORIMATINIB; OCTREOTIDE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TOXICITY; MALE; MONOTHERAPY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OCTREOTIDE; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PYRIMIDINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38349044462     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.10.041     Document Type: Article

References (34)

1. Bergers G., Song S., Meyer-Morse N., Bergsland E., and Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111 (2003) 1287-1295
2. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose ''chemo-switch'' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 23 (2005) 939-952
3. Kerbel S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. 4 (2004) 423-436
4. Pietras K., Sjoblom T., Rubin K., Heldin C.H., and Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 3 (2003) 439-443
5. Baker D.E. Imatinib mesylate. Rev. Gastroenterol. Disord. 2 (2002) 75-86
6. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
7. Czochra P., Kutzner P., Maass T., Thieringer F., Haennchen M., Schirmacher P., Longerich P., Lohse A., Galle P., and Kanzler S. Accelerated tumor progression in chemical carcinogenesis model in PDGF-B transgenic mice. Hepatology 44 suppl 1 (2006) A122
8. Poon R.T., Lau C., Yu W.C., et al. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol. Rep. 11 (2004) 1077-1084
9. Kouroumalis E., Skordilis P., Thermos K., et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42 (1998) 442-447
10. Dimitroulopoulos D., Xinopoulos D., Tsamakidis K., et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 49 (2002) 1245-1250
11. Treiber G., Rocken C., Wex T., and Malfertheiner P. Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer. Z. Gastroenterol. 45 (2007) 369-377
12. Jia W.D., Xu G.L., Xu R.N., et al. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J. Cancer Res. Clin. Oncol. 129 (2003) 327-334
13. Jia W.D., Xu G.L., Sun H.C., et al. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo. Hepatobiliary Pancreat Dis. Int. 2 (2003) 404-409
14. Poon R.T., Ng I.O., Lau C., et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann. Surg. 233 (2001) 227-235
15. Treiber G., Wex T., Rocken C., Fostitsch P., and Malfertheiner P. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 132 (2006) 699-708
16. Schleyer E., Pursche S., Kohne C.H., Schuler U., Renner U., Gschaidmeier H., Freiberg-Richter J., Leopold T., Jenke A., Bonin M., Bergemann T., le Coutre P., Gruner M., Bornhauser M., Ottmann O.G., and Ehninger G. Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 799 (2004) 23-36
17. Heinzel G., Wloszczak R., and Thomann P. Topfit 2.0 pharmacokinetic and pharmacodynamic data analysis system for the PC. first ed. (1993), Fischer, Stuttgart
18. Bornhauser M., Pursche S., Bonin M., Freiberg-Richter J., Jenke A., Illmer T., Ehninger G., and Schleyer E. Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib. J. Clin. Oncol. 23 (2005) 3855-3856 author reply 3857-8.
19. le Coutre P., Kreuzer K.A., Pursche S., Bonin M., Leopold T., Baskaynak G., Dorken B., Ehninger G., Ottmann O., Jenke A., Bornhauser M., and Schleyer E. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother. Pharmacol. 53 (2004) 313-323
20. O'Brien S.G., Meinhardt P., Bond E., Beck J., Peng B., Dutreix C., Mehring G., Milosavljev S., Huber C., Capdeville R., and Fischer T. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br. J. Cancer 89 (2003) 1855-1859
21. Bauer S., Hagen V., Pielken H.J., Bojko P., Seeber S., and Schutte J. Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function. Anticancer Drugs 13 (2002) 847-849
22. Gschwind H.P., Pfaar U., Waldmeier F., Zollinger M., Sayer C., Zbinden P., Hayes M., Pokorny R., Seiberling M., Ben-Am M., Peng B., and Gross G. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab. Dispos. 33 (2005) 1503-1512
23. Schmidli H., Peng B., Riviere G.J., Capdeville R., Hensley M., Gathmann I., Bolton A.E., and Racine-Poon A. IRIS Study Group. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br. J. Clin. Pharmacol. 60 (2005) 35-44
24. Judson I., Ma P., Peng B., Verweij J., Racine A., di Paola E.D., van Glabbeke M., Dimitrijevic S., Scurr M., Dumez H., and van Oosterom A. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother. Pharmacol. 55 (2005) 379-386
25. Dutreix C., Peng B., Mehring G., Hayes M., Capdeville R., Pokorny R., and Seiberling M. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother. Pharmacol. 54 (2004) 290-294
26. Nikolova Z., Peng B., Hubert M., Sieberling M., Keller U., Ho Y.Y., Schran H., and Capdeville R. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemother. Pharmacol. 53 (2004) 433-438
27. Peng B., Hayes M., Resta D., Racine-Poon A., Druker B.J., Talpaz M., Sawyers C.L., Rosamilia M., Ford J., Lloyd P., and Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 22 (2004) 935-942
28. Frye R.F., Fitzgerald S.M., Lagattuta T.F., Hruska M.W., and Egorin M.J. Effect of St. John's wort on imatinib mesylate pharmacokinetics. Clin. Pharmacol. Ther. 76 (2004) 323-329
29. Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin. Oncol. 31 2 Suppl 6 (2004) 18-23
30. Ribom D., Larsson A., Pietras K., and Smits A. Growth factor analysis of low-grade glioma CSF: PDGF and VEGF are not detectable. Neurol. Sci. 24 (2003) 70-73
31. Pietras K., Rubin K., Sjoblom T., Buchdunger E., Sjoquist M., Heldin C.H., and Ostman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62 (2002) 5476-5484
32. Eckel F., von Delius S., Mayr M., Dobritz M., Fend F., Hosius C., Schleyer E., Schulte-Frohlinde E., Schmid R.M., and Lersch C. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology 69 (2005) 363-367
33. van Roeyen C.R., Ostendorf T., Denecke B., Bokemeyer D., Behrmann I., Strutz F., Lichenstein H.S., LaRochelle W.J., Pena C.E., Chaudhuri A., and Floege J. Biological responses to PDGF-BB versus PDGF-DD in human mesangial cells. Kidney Int. 69 (2006) 1393-1402
34. Treiber G. Systemic treatment of hepatocellular carcinoma. Dig. Dis. 19 (2001) 311-323